MBX (MBX Biosciences, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by MBX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Salomon Azoulay | Chief Medical Officer | Sell | — | — |
| 2026-08-04 | John W Smither | Chief Financial Officer | A | — | — |
| 2026-08-04 | Steven L. Hoerter | President and CEO | A | — | — |
| 2026-06-05 | Patrick J Heron | Director | A | — | — |
| 2026-06-05 | Laurie Stelzer | Director | A | — | — |
| 2026-06-05 | Edward T Mathers | Director | A | — | — |
| 2026-06-05 | Ora H. Pescovitz | Director | A | — | — |
| 2026-06-05 | Tiba Aynechi | Director | A | — | — |
| 2026-06-05 | Steven Ryder | Director | A | — | — |
| 2026-06-05 | Steven L. Hoerter | Director | A | — | — |
| 2026-05-11 | Salomon Azoulay | Chief Medical Officer | MIXED | — | — |
| 2026-05-08 | P. Kent Hawryluk | President & CEO | Sell | — | — |
| 2026-05-08 | Salomon Azoulay | Chief Medical Officer | Sell | — | — |
| 2026-05-04 | Steven L. Hoerter | Director | A | — | — |
| 2026-04-22 | Steven L. Hoerter | Director | A | — | — |
| 2026-04-22 | Steven L. Hoerter | Director | A | — | — |
| 2026-03-16 | P. Kent Hawryluk | President & CEO | Buy | — | — |
| 2026-02-27 | P. Kent Hawryluk | President & CEO | M | — | — |
| 2026-02-03 | P. Kent Hawryluk | President & CEO | A | — | — |
| 2026-02-03 | Salomon Azoulay | Chief Medical Officer | A | — | — |
| 2026-02-03 | Richard Bartram | Chief Financial Officer | A | — | — |
| 2026-01-22 | Laurie Stelzer | Director | A | — | — |
| 2025-11-25 | Steven L. Hoerter | Director | A | — | — |
| 2025-11-07 | Steven L. Hoerter | Director | A | — | — |
| 2025-10-28 | P. Kent Hawryluk | President & CEO | M | — | — |
| 2025-10-21 | P. Kent Hawryluk | President & CEO | Buy | — | — |
| 2025-10-20 | Steven L. Hoerter | Director | Buy | — | — |
| 2025-09-30 | Frazier Life Sciences X, L.P. | 10%+ Owner | Buy | — | — |
| 2025-06-06 | JAMES M CORNELIUS | Director | A | — | — |
| 2025-06-06 | Patrick J Heron | Director | A | — | — |
| 2025-06-06 | Steven L. Hoerter | Director | A | — | — |
| 2025-06-06 | Steven Ryder | Director | A | — | — |
| 2025-06-06 | Edward T Mathers | Director | A | — | — |
| 2025-06-06 | Tiba Aynechi | Director | A | — | — |
| 2025-06-06 | Ora H. Pescovitz | Director | A | — | — |
| 2025-04-10 | Ora H. Pescovitz | Director | Buy | — | — |
| 2025-04-09 | Steven L. Hoerter | Director | A | — | — |
| 2025-02-19 | CARL L GORDON | Director | Buy | — | — |
| 2025-02-19 | OrbiMed Capital GP VII LLC | Director | Buy | — | — |
| 2025-02-05 | Salomon Azoulay | Chief Medical Officer | A | — | — |
| 2025-02-05 | Richard Bartram | Chief Financial Officer | A | — | — |
| 2025-02-05 | P. Kent Hawryluk | President & CEO | Buy | — | — |
| 2024-09-17 | JAMES M CORNELIUS | Director | C | — | — |
| 2024-09-17 | Tiba Aynechi | Director | MIXED | — | — |
| 2024-09-17 | CARL L GORDON | Director | MIXED | — | — |
| 2024-09-17 | Carmen Chang | 10%+ Owner | MIXED | — | — |
| 2024-09-17 | Patrick J Heron | Director | MIXED | — | — |
| 2024-09-17 | FOREST BASKETT | 10%+ Owner | MIXED | — | — |
| 2024-09-17 | P. Kent Hawryluk | President & CEO | C | — | — |
| 2024-09-17 | Paul Edward Walker | 10%+ Owner | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 5,219,440 | — |
| — | 10%+ Owner | 4,552,774 | — |
| — | Director | 3,927,774 | — |
| — | 10%+ Owner | 3,614,486 | — |
| — | 10%+ Owner | 3,614,486 | — |
| — | Director | 3,205,930 | — |
| — | 10%+ Owner | 3,114,486 | — |
| — | 10%+ Owner | 3,114,486 | — |
| — | 10%+ Owner | 3,114,486 | — |
| — | 10%+ Owner | 3,114,486 | — |
| — | 10%+ Owner | 1,790,122 | — |
| — | Director | 1,386,335 | — |
| — | President & CEO | 1,214,444 | — |
| — | 10%+ Owner | 1,023,103 | — |
| — | Director | 1,023,103 | — |
| — | 10%+ Owner | 1,023,103 | — |
| — | 10%+ Owner | 1,023,103 | — |
| — | Director | 747,887 | — |
| — | Director | 653,787 | — |
| — | President and CEO | 102,938 | — |
| — | Director | 102,082 | — |
| — | Chief Financial Officer | 28,000 | — |
| — | Director | 24,329 | — |
| — | Chief Financial Officer | 15,000 | — |
| — | Chief Medical Officer | 14,399 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MBX quote page; the site-wide leaderboard is on the insider transactions hub.